RxDoctor Payments Data

Tamara Barsik, MD

Internal Medicine · Allen, TXNPI 1356320378

Payments from drug & device makers

$3,516in general payments, 2019–2025

Across 198 payments — averaging $17.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$450
  • Amgen$367
  • Novo Nordisk$221
  • Acadia Pharmaceuticals Inc$173
  • GSK$172
  • Pfizer$168
  • plus $2K from 38 others

What the payments were for

  • Food & beverage$3,516100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,516 in reported general payments places this provider in the 80th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$415,644
Medicare patients
927
Services billed
4,331

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban337$156,308
GemtesaVibegron234$56,997
NuedextaDextromethorphan Hbr/Quinidine67$51,343
OzempicSemaglutide50$50,885
JardianceEmpagliflozin97$47,753
JanuviaSitagliptin Phosphate84$35,337
TrulicityDulaglutide33$35,099
XareltoRivaroxaban88$32,619
CreonLipase/Protease/Amylase19$28,382
MounjaroTirzepatide23$23,198
TradjentaLinagliptin55$19,557
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$17,992
MyrbetriqMirabegron14$14,311
EntrestoSacubitril/Valsartan33$12,658
Potassium Chloride337$11,548

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$168$156,308337 claims
Boehringer IngelheimJardiance, Tradjenta$47$67,310152 claims
Lilly USA, LLCTrulicity, Mounjaro$57$58,29756 claims
Sumitomo Pharma America, Inc.Gemtesa$59$56,997234 claims
Avanir Pharmaceuticals, Inc.Nuedexta$49$51,34367 claims
Novo NordiskOzempic$221$50,88550 claims
AbbVieCreon, Linzess$136$39,17931 claims
Johnson & JohnsonXarelto$148$32,61988 claims
GSKTrelegy Ellipta, Incruse Ellipta$172$23,91726 claims
AstraZenecaSymbicort, Farxiga, Brilinta$58$19,34162 claims
Astellas Pharma US IncMyrbetriq$15$14,31114 claims
NovartisEntresto$450$12,65833 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Allen

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →